FDA Proposes Reforms to Speed Early Clinical Trials, Aid Smaller Biotechs

The FDA's fiscal year 2027 budget request, published April 3, contains a proposal that could fundamentally reshape how experimental drugs enter first-in-human testing: a new "optional, risk-based" expedited Investigational New Drug pathway aimed at reducing the regulatory burden on smaller biotechnology companies and accelerating the pace at which novel candidates reach Phase 1 trials.

The agency proposed the new pathway as a way to speed experimental drugs into human testing, explicitly framing it as an effort to match a regulatory framework in China that has shifted early drug development activity away from the U.S. Under the proposal, the pathway would be available for experimental drugs with existing preclinical data that can be confirmed without animal tests, and the FDA said it "would create an accelerated path" to U.S.-based Phase 1 clinical programs while lowering drug development costs.

President Trump's budget allocates $7.23 billion for the FDA in 2027, an increase of approximately $232 million, or 3.2%, from 2026. That increase stands in sharp contrast to a 12% funding cut across the broader Department of Health and Human Services. FDA Commissioner Marty Makary, in his opening letter for the proposal document, said the 2027 budget would facilitate the agency's transition "from a reactionary system to a proactive system," with new pathways intended to expedite drug development, boost national security, and promote "radical transparency."

The proposals carry particular weight for smaller biotech firms, which frequently lack in-house regulatory expertise and the financial depth to absorb prolonged pre-trial back-and-forth with regulators. Earlier and more frequent engagement with the agency, clearer guidance on how exploratory biomarker and safety studies can transition into pivotal programs, and support for adaptive trial designs are all part of the broader reform package under discussion. If enacted, those changes could allow academic spinouts and early-stage companies to accelerate development timelines and improve their odds of reaching mid-stage trials.

Separately, the FDA also plans to amend existing regulations to allow disclosure of "information on deficiencies in safety and efficacy data" for rejected drugs or biologics, a move it said "could help others prevent similar deficiencies in their own development programs."

The regulatory signaling has immediate industry implications. Takeda moved this week to delay its pursuit of a brain drug developed in partnership with Denali Therapeutics, a decision that illustrates how sensitive corporate pipeline timing remains to regulatory clarity. Two startups, Syneron Bio and Stipple Bio, separately closed megaround financings, underscoring that capital continues to flow toward early-stage biotech assets even amid broader uncertainty.

Reform advocates argue that current early-development processes impose disproportionate costs that narrow therapeutic diversity and slow patient access. Clinical trial experts, however, caution that lowering entry barriers must not compromise the dose-escalation controls, pharmacokinetic assessments, and preclinical safety margins that protect participants in first-in-human studies. Those tensions will likely surface in any stakeholder comment period the FDA convenes. The concrete test of these proposals will come in the months ahead, as draft guidance documents and formal budget language determine whether the expedited IND concept moves from a budget line item to binding policy before the fiscal year 2027 cycle, which begins October 1.